Table 1.
Demographic data and clinical characteristics of carrier and noncarrier group of SNCA-rs11931074 in PD patients.
| Carriers | Noncarriers | p | SC/OR (95% CI) | |||
|---|---|---|---|---|---|---|
| N | X ± S/N ∗ (F) | N | X ± S/N ∗ (F) | |||
| Age of enrollment | 611 | 62.52 ± 12.88 | 113 | 64.80 ± 12.11 | NA | NA |
| Age of onset | 611 | 57.91 ± 13.44 | 113 | 60.02 ± 12.35 | NA | NA |
| Disease course | 611 | 4.61 ± 4.42 | 113 | 4.78 ± 3.97 | 0.700 | 0.446 (−1.046 to 0.703)# |
| Gender, male | 611 | 352 (57.6%) | 113 | 64 (56.6%) | NA | NA |
| UPDRS I | 522 | 1.76 ± 1.95 | 91 | 2.03 ± 2.04 | 0.226 | −0.049 |
| UPDRS II | 522 | 12.41 ± 7.13 | 91 | 14.26 ± 6.90 | 0.035 | −0.083 |
| UPDRS III | 553 | 27.42 ± 15.77 | 97 | 34.18 ± 16.53 | ≤0.001 | −0.140 |
| H-Y | 452 | 2.26 ± 0.95 | 80 | 2.38 ± 0.89 | 0.487 | −0.030 |
| LEDD | 469 | 546.78 ± 300.44 | 83 | 594.09 ± 115.41 | 0.164 | −0.060 |
| CCI | 611 | 0.10 ± 0.37 | 113 | 0.21 ± 0.47 | 0.009 | −0.097 |
| Cognitive impairment | 247 | 63 (25.5%) | 39 | 12 (30.8%) | 0.618 | 0.824 (0.386–1.761) |
| WO | 403 | 51 (12.7%) | 71 | 7 (9.9%) | 0.502 | 1.331 (0.578–3.068) |
UPDRS I, II, and III: Unified Parkinson's Disease Rating Scale parts I, II, and III; H-Y: Hoehn and Yahr Scale; LEDD: levodopa equivalent daily dose; CCI: Charlson Comorbidity Index score; WO: wearing-off phenomenon evaluated by the 9-item wearing-off questionnaire (WOQ-9); N: the total number of carriers and noncarriers of SNCA-rs11931074 in PD patients; SC: standardized coefficient; OR: odds ratio; CI: confidence interval; NA: not available. #Standard error (95% CI). Cognitive impairment was assessed by Mini-Mental State Examination (MMSE). Numerical variable was presented as mean and standard deviation (X ± S); categorical variable was presented as the number of carriers or noncarriers and its relevant frequency separately [N ∗ (F)]. p value <0.05 was considered statistically significant and is shown in bold.